Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Oncol Rep. 2002 Sep;4(5):415-23.

Changing role and decreasing size: current trends in radiotherapy for Hodgkin's disease.

Author information

1
Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, Weill Medical College of Cornell University, 1275 York Avenue, New York, NY 10021, USA. yahalomj@mskcc.org

Abstract

Radiotherapy, the first cancer treatment modality that offered cure, is still considered to be the most effective "single agent" in treating Hodgkin's disease (HD). Yet, the role of radiotherapy in HD has changed dramatically with the advent of effective combination chemotherapy and the rising concern of long-term complications associated with successful treatment of HD. The new principles of integrating radiotherapy into a combined-modality regimen for HD at different prognostic stages are reviewed here, along with the effect of this new role on radiation field size and design.

PMID:
12162917
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center